Before the market open on Tuesday, the bio-pharmaceutical company reported earnings of 43 cents per share, surpassing analysts' forecasts for 19 cents per share.
Revenue of $55.4 million beat Wall Street's estimates for $42.72 million.
Additionally, Sucampo projected 2016 revenue to range between $195 million to $205 million, in-line with Wall Street's projections for $201.72 million.
So far today, 1.14 million shares of Sucampo have traded, well above the company's 30-day average of about 428,000 shares.
Separately, recently, TheStreet Ratings objectively rated this stock according to its "risk-adjusted" total return prospect over a 12-month investment horizon. Not based on the news in any given day, the rating may differ from Jim Cramer's view or that of this articles's author.
TheStreet Ratings rates this stock as a "buy" with a ratings score of B. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, reasonable valuation levels and impressive record of earnings per share growth. We feel its strengths outweigh the fact that the company has had lackluster performance in the stock itself.
You can view the full analysis from the report here: SCMP